CurifyLabs unveils “Create” software platform for 3D-printed formulations

CurifyLabs has introduced a new generation of its platform for pharmacy-standard preparation of patient-specific medicines. At its core is “CurifyLabs Create,” a tool that enables pharmaceutical personnel to digitally model formulations and prepare them directly for 3D printing. The company positions the solution as a complement to its existing compounding system of software, GMP-compliant base materials, and additive manufacturing. According to CurifyLabs, the approach has already been validated with more than 100 pharmacists. Compounding has traditionally been characterized by manual, error-prone steps; the new software is intended to structure and document this work.

Create allows formulation either from pure active pharmaceutical ingredients (APIs) or from milled finished products. The output parameters—such as geometry, mass, porosity, and drug distribution—are calculated for the print path and stored as a process data record. In parallel, CurifyLabs is expanding its range of CURABLEND bases that support multiple dosage forms, including tablets, solutions/suspensions, thin oral films, suppositories, and troches. Accompanying this, the platform integrates quality-assurance functions such as electronic records, audit trails, and validated processes, which the provider says are aligned with FDA and GMP requirements.

“With our latest software release, we’re making compounding faster, more precise, and more adaptable than ever before,” said Charlotta Topelius, CurifyLabs CEO and Founder. “CurifyLabs Create empowers pharmacists to personalize therapies at the point of care, while our expanded excipient bases enable a wide range of patient-friendly dosage forms.”

In operation, the system is said to be up to four times faster than purely manual work, while enforcing reproducible process steps and traceability. Against the backdrop of growing demand for individualized dosages—driven by pharmacogenomics and the specific needs of children, older adults, and multimorbid patients—CurifyLabs sees a gap between mass production and one-off manufacturing.

“The demand for personalized compounding is accelerating, fueled by advances in pharmacogenomics and the need for tailored dosing—especially for children, seniors, and patients with complex conditions,” added Topelius. “With our enhanced software, working hand-in-hand with our first-of-its-kind 3D printing technology, we’re not just improving compounding—we’re redefining it for the future of healthcare.”

For pharmacies seeking to introduce additive processes with quality assurance, end-to-end documentation and the selection of standardized excipient matrices are particularly relevant.